Abstract
Ovarian cancer, the fifth most common neoplasia in women, presents challenges in diagnosis and treatment, often resulting in poor prognosis due to advanced stage at diagnosis and limited treatment options. Platinum-based chemotherapy and surgery have been the mainstay treatments, but efforts to improve outcomes with additional cytotoxic drugs have yielded mixed results. Angiogenesis plays a crucial role in tumor growth and metastasis, leading to the investigation of bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF). Clinical trials have demonstrated its efficacy in delaying disease progression in ovarian cancer. This case report illustrates the successful use of neoadjuvant chemotherapy followed by surgery and maintenance therapy with bevacizumab and olaparib in a patient with advanced ovarian cancer, highlighting the potential benefits of this treatment approach in improving survival outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Saudi Journal of Medical and Pharmaceutical Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
